Top-News
  • Depot
  • Watchlist
  • Glocke
  • Handeln

    • Swedish Orphan Biovitrum News

    22,88 € +0,26% +0,06 €
    24.04.24 17:17:16 Frankfurt aktualisieren | Orderbuch | Mehr Kurse »
    WKN: A0LA5K
    ISIN: SE0000872095
    US-Symbol: BIOVF
    Typ: Aktie

    Swedish Orphan Biovitrum News

    17.07.23 - dpa-AFX
    AKTIE IM FOKUS: Morphosys nähern sich Jahreshoch - Weiteres Lob für Pelabresib
    Nach einer optimistischeren Studie der Deutschen Bank haben Aktien von Morphosys am Montag im frühen Handel bis zu 6,6 Prozent zugelegt auf 29,14 Euro. Damit steuern die ...
    10.05.23 - Der Aktionär
    89 Prozent Aufschlag: Nächster Übernahme‑Hammer im Biotech‑Sektor
    02.03.23 - PR Newswire
    Positive topline results from pivotal XTEND-Kids phase 3 study of efanesoctocog alfa in children under 12 years of age with haemophilia A: Swedish Orphan Biovitrum AB
    Positive topline results from pivotal XTEND-​Kids phase 3 study of efanesoctocog alfa in children under 12 years of age with haemophilia A: Swedish Orphan Biovitrum AB PR Newswire
    02.03.23 - PR Newswire
    Positive topline results from pivotal XTEND-Kids phase 3 study of efanesoctocog alfa in children under 12 years of age with haemophilia A: Swedish Orphan Biovitrum AB
    Positive topline results from pivotal XTEND-​Kids phase 3 study of efanesoctocog alfa in children under 12 years of age with haemophilia A: Swedish Orphan Biovitrum AB PR Newswire
    19.07.22 - PLX
    SOBI Q2 Revenue SEK 3,876 Million vs. Estimate SEK 3,600 Million
    (PLX AI) – SOBI Q2 EBIT SEK 423 million.
    10.07.22 - PR Newswire
    Pivotal data demonstrate once-weekly efanesoctocog alfa provides superior bleed protection compared to prior factor prophylaxis
    Pivotal data demonstrate once-​weekly efanesoctocog alfa provides superior bleed protection compared to prior factor prophylaxis PR Newswire
    28.04.22 - PLX
    SOBI Q1 Results Better Than Expected: Revenue Outlook Unchanged
    (PLX AI) – SOBI Q1 revenue SEK 4,925 million vs. estimate SEK 4,485 million. • Q1 EBITA SEK 1,951 million vs. estimate SEK 1,715 million • Revenue is anticipated to grow by a mid to ...
    10.02.22 - PLX
    SOBI Sees 2022 Revenue Growth Mid-to Single-Digit Percentage
    (PLX AI) – Q4 revenue SEK 4,896 million vs. estimate SEK 4,874 million • Q4 EBITA SEK 2,002 million • Q4 adjusted EBITA SEK 2,002 million • Q4 EPS SEK 4.21 • SOBI 2022 Revenue ...
    22.10.21 - PLX
    SOBI Q3 EBITA SEK 1,166 Million
    (PLX AI) – SOBI Q3 revenue SEK 3,761 million. • Outlook FY revenue SEK 14,500-15,000 million • Outlook FY EBITA margin 33-35%
    11.10.21 - PLX
    SOBI Q3 Earnings Beat Consensus; Outlook Raised
    (PLX AI) – SOBI reports preliminary Q3 earnings that beat consensus expectations and also raised its full-year outlook. • Q3 EBITA SEK 1,170 million vs. estimate SEK 708 million • Q3 ...
    11.10.21 - PLX
    SOBI Q3 EBITA SEK 1,170 Million
    (PLX AI) – SOBI Q3 revenue SEK 3,760 million. • Outlook FY revenue SEK 14,500-15,000 million • Outlook FY EBITA margin 33-35%
    02.09.21 - PLX
    SOBI Board Recommends SEK 235 per Share Offer from Advent & Aurora
    (PLX AI) – SOBI recommends that the shareholders accept offer of SEK 235 per share from Advent International and Aurora Investment through Agnafit Bidco. • Offer values SOBI at ...
    21.07.21 - PLX
    SOBI Q2 EBITA SEK 922 Million vs. Estimate SEK 830 Million
    (PLX AI) – SOBI Q2 revenue SEK 3,211 million vs. estimate SEK 3,034 million. • Outlook FY revenue SEK 14,000-15,000 million • Outlook FY EBITA margin 30-35%
    08.07.21 - PR Newswire
    Invitation - Presentation of Sobi's Q2 2021 results
    Invitation - Presentation of Sobi's Q2 2021 results PR Newswire
    07.07.21 - PR Newswire
    Sobi to present data at the ISTH 2021 within rare haematology diseases
    Sobi to present data at the ISTH 2021 within rare haematology diseases PR Newswire
    07.07.21 - PR Newswire
    Sobi to present data at the ISTH 2021 within rare haematology diseases
    Sobi to present data at the ISTH 2021 within rare haematology diseases PR Newswire
    01.06.21 - PR Newswire
    Sobi at EHA virtual congress 2021: focus on results in PNH and treatment for ITP
    Sobi at EHA virtual congress 2021: focus on results in PNH and treatment for ITP PR Newswire
    01.06.21 - PR Newswire
    Sobi at EHA virtual congress 2021: focus on results in PNH and treatment for ITP
    Sobi at EHA virtual congress 2021: focus on results in PNH and treatment for ITP PR Newswire
    25.05.21 - PR Newswire
    Positive top-line results from the phase 3 PRINCE study of pegcetacoplan in treatment-naïve patients with PNH
    Positive top-line results from the phase 3 PRINCE study of pegcetacoplan in treatment-naïve patients with PNH PR Newswire
    25.05.21 - PR Newswire
    Positive top-line results from the phase 3 PRINCE study of pegcetacoplan in treatment-naïve patients with PNH
    Positive top-line results from the phase 3 PRINCE study of pegcetacoplan in treatment-naïve patients with PNH - Pegcetacoplan demonstrated statistical superiority on the co-...

    Newssuche

    Videos

    newspaper
    24.04.24
    Technical Trading: AUD/USD mit Mega Chance
    AUD/USD Long Typ: Turbo Open End WKN: UM0EHU Hebel: 6,42 Laufzeit: OpenEnd Einstieg: Market ... Mehr »